Ruxolitinib
- Generic Name
- Ruxolitinib
- Brand Names
- Jakafi, Jakavi, Opzelura
- Drug Type
- Small Molecule
- Chemical Formula
- C17H18N6
- CAS Number
- 941678-49-5
- Unique Ingredient Identifier
- 82S8X8XX8H
- Background
Ruxolitinib, formerly known as INCB018424 or INC424, is an anticancer drug and a Janus kinase (JAK) inhibitor. It is a potent and selective inhibitor of JAK1 and JAK2, which are tyrosine kinases involved in cytokine signalling and hematopoiesis. Myeloproliferative neoplasms, such as myelofibrosis and polycythemia vera, are often characterized by aberrant act...
- Indication
Ruxolitinib is indicated for the treatment of the following conditions:
Topical ruxolitinib is indicated for:
- Associated Conditions
- Acute Graft-Versus-Host Disease (GVHD), Chronic Graft-Versus-Host Disease, Non-segmental Vitiligo, Post Polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis (Post-ET MF), Primary Myelofibrosis (PMF), High risk Myelofibrosis, Intermediate risk Myelofibrosis, Mild Atopic dermatitis, Moderate Atopic dermatitis, Refractory Polycythemia vera
- Associated Therapies
- -
Ruxolitinib Phosphate and Chemotherapy Given Before and After Reduced Intensity Donor Stem Cell Transplant in Treating Patients With Myelofibrosis
- Conditions
- Interventions
- First Posted Date
- 2016-09-28
- Last Posted Date
- 2023-12-12
- Lead Sponsor
- City of Hope Medical Center
- Target Recruit Count
- 18
- Registration Number
- NCT02917096
- Locations
- 🇺🇸
City of Hope Medical Center, Duarte, California, United States
Ruxolitinib Combined With Ibrutinib in Chronic Lymphocytic Leukemia Patients
- Conditions
- Interventions
- First Posted Date
- 2016-09-23
- Last Posted Date
- 2017-03-13
- Lead Sponsor
- Sunnybrook Health Sciences Centre
- Target Recruit Count
- 36
- Registration Number
- NCT02912754
- Locations
- 🇨🇦
Sunnybrook Odette Cancer Center, Toronto, Ontario, Canada
Study Of Ruxolitinib (INCB018424) With Preoperative Chemotherapy For Triple Negative Inflammatory Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2016-08-23
- Last Posted Date
- 2024-10-17
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 23
- Registration Number
- NCT02876302
- Locations
- 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Mayo Clinic, Rochester, Minnesota, United States
🇺🇸Duke University Medical Center, Durham, North Carolina, United States
PTCy and Ruxolitinib GVHD Prophylaxis in Myelofibrosis
- First Posted Date
- 2016-06-20
- Last Posted Date
- 2019-04-04
- Lead Sponsor
- St. Petersburg State Pavlov Medical University
- Target Recruit Count
- 20
- Registration Number
- NCT02806375
- Locations
- 🇷🇺
First Pavlov State Medical University of St. Petersburg, Saint-Petersburg, Russian Federation
Long-Term Side Effects of Ruxolitinib in Treating Patients With Myelofibrosis
- Conditions
- Interventions
- First Posted Date
- 2016-05-27
- Last Posted Date
- 2024-08-26
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 8
- Registration Number
- NCT02784496
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia
- Conditions
- Interventions
- First Posted Date
- 2016-03-31
- Last Posted Date
- 2024-11-29
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 171
- Registration Number
- NCT02723994
- Locations
- 🇺🇸
Sinai Hospital of Baltimore, Baltimore, Maryland, United States
🇺🇸Childrens Hospital of Pittsburgh, Pittsburgh, Pennsylvania, United States
🇺🇸Texas Childrens Hospital, Houston, Texas, United States
A Study of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis
- Conditions
- Interventions
- First Posted Date
- 2016-03-24
- Last Posted Date
- 2024-05-01
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 74
- Registration Number
- NCT02718300
- Locations
- 🇺🇸
California Cancer Associates For Research and Excellence, Fresno, California, United States
🇺🇸Baylor Scott and White Research Institute, Dallas, Texas, United States
🇺🇸University of Chicago Medical Center, Chicago, Illinois, United States
Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies
- Conditions
- Interventions
- First Posted Date
- 2016-03-17
- Last Posted Date
- 2022-04-28
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 137
- Registration Number
- NCT02711137
- Locations
- 🇺🇸
Yale University, New Haven, Connecticut, United States
🇺🇸Hematology - Oncology Associates of Treasure Coast, Port Saint Lucie, Florida, United States
🇺🇸The Methodist Hospital, Houston, Texas, United States
Genomics-Based Target Therapy for Children With Relapsed or Refractory Malignancy
- Conditions
- Interventions
- First Posted Date
- 2015-12-23
- Last Posted Date
- 2020-03-19
- Lead Sponsor
- Samsung Medical Center
- Target Recruit Count
- 90
- Registration Number
- NCT02638428
- Locations
- 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of
Dose Escalation Study to Determine the Maximum Tolerated Dose of the Combination of Ruxolitinib and Bortezomib in Patients With Relapsed or Refractory Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2015-11-24
- Last Posted Date
- 2021-12-20
- Lead Sponsor
- University of Michigan Rogel Cancer Center
- Target Recruit Count
- 15
- Registration Number
- NCT02613598
- Locations
- 🇺🇸
University of Michgan Comprehensive Cancer Center, Ann Arbor, Michigan, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.